Cabanillas ME et al. Larotrectinib treatment of advanced TRK fusion thyroid cancer. ESMO 2020;Abstract 1916P.

Cocco E et al. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol 2019;15(12):731-41. Abstract

Gatalica Z et al. Molecular characterization of cancers with NTRK gene fusions. Modern Pathol 2019;32(1):147-53. Abstract

Hong DS et al. Larotrectinib in patients with TRK fusion-positive solid tumours: A pooled analysis of three phase 1/2 clinical trials. Lancet Oncol 2020;21(4):531-40. Abstract

Pekova B et al. RET, NTRK, ALK, BRAF, and MET fusions in a large cohort of pediatric papillary thyroid carcinomas. Thyroid 2020;30(12):1771-80. Abstract

Sherman EJ et al. Selpercatinib efficacy and safety in patients with RET-altered thyroid cancer: A clinical trial update. ASCO 2021;Abstract 6073.

Subbiah V et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): A multi-cohort, open-label, registrational, phase 1/2 study. Lancet Diabet Endocrinol 2021;9(8):491-501. Abstract

Subbiah V et al. State-of-the-art strategies for targeting RET-dependent cancers. J Clin Oncol 2020;38(11):1209-21. Abstract

Wirth LJ et al. Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med 2020;383(9):825-35. Abstract